Testing TORL-5-700 for advanced lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called TORL-5-700 for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see how safe it is and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed B-cell non-Hodgkin lymphoma, such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or others.
- Your overall health should allow you to be up and about at least half the day (ECOG score 0-2).
- You must have at least one tumor that can be measured on scans.
- You need to have a sample of your tumor tissue available for testing.
- Your major organs must be working well enough.
- You cannot have T-cell lymphoma, CLL/SLL, Burkitt lymphoma, high-grade B-cell lymphoma, or lymphoma that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
Hear when a new Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.